Celladon Corporation (CLDN) is trading at an unusually high volume in mid-morning trading on Monday with 2 million shares changing hands. It is currently at more than 3x its 3-month average daily volume. CLDN gained over 13% in early trading after its pending merger partner Eiger BioPharmaceuticals confirmed receipt of Orphan Designation from the FDA.
In the past 52 weeks, shares of San Diego, California-based clinical-stage biotechnology firm have traded between a low of $1.00 and a high of $28.25 and are now at $1.61.
Shares are down 88.39% year-over-year and 92.58% year-to-date.
Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!